Otolaryngology: from the daily briefing
Every daily briefing item tagged otolaryngology, newest first. The weekly roundup is on the otolaryngology page.
- FDA grants accelerated approval to subcutaneous amivantamab for head and neck cancer after platinum and immunotherapy, with a 42% response rateRegulation
- FDA grants accelerated approval to Rybrevant Faspro for recurrent or metastatic head and neck squamous cell cancerRegulation
- FDA places external mechanical stimulators for congestion relief in class II with special controlsRegulation
- Sodium fluoride linked to hearing stabilization in otosclerosis in a meta-analysis of 2,352 patientsEvidence
- Laryngeal mask airway cuts respiratory adverse events to 22.5% from 57.5% with a tube in children's adenotonsillectomyEvidence
- Cochlear recalls Nucleus Nexa implants with the Contour Advance electrode over incomplete electrode weldsIncident
- FDA approves Voceryq, the first plasmid DNA immunotherapy, for adults with recurrent respiratory papillomatosisRegulation
- Petosemtamab plus Keytruda cut risk of death by half vs. Keytruda alone in head and neck cancer, early analysis showsEvidence
- Petosemtamab plus Keytruda halves risk of death in PD-L1-positive recurrent or metastatic head and neck cancerEvidence
- Joe DiMaggio Children's Hospital to offer Inspire therapy for teens with Down syndrome and obstructive sleep apneaDeployment
- International consensus guideline on curative-intent care of de novo metastatic nasopharyngeal carcinomaEvidence
Latest news
Tagged otolaryngology, from the daily briefing
- FDA grants accelerated approval to subcutaneous amivantamab for head and neck cancer after platinum and immunotherapy, with a 42% response rate
- FDA grants accelerated approval to Rybrevant Faspro for recurrent or metastatic head and neck squamous cell cancer
- FDA places external mechanical stimulators for congestion relief in class II with special controls